Auspex’s Huntington’s drug hits the mark in Phase III

Damian Garde

Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way for a 2015 FDA filing.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS